Prothena FY2026 Earnings Forecast Increased by HC Wainwright

Prothena Corporation plc (NASDAQ:PRTA) – Stock analysts at HC Wainwright lifted their FY2026 EPS estimates for Prothena in a report released on Friday, November 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of ($0.44) for the year, up from their previous forecast of ($0.47). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Prothena’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Prothena’s Q4 2026 earnings at ($0.44) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.38) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at $0.96 EPS, FY2029 earnings at ($1.48) EPS and FY2030 earnings at $2.26 EPS.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). The business had revenue of $0.62 million for the quarter, compared to analysts’ expectations of $9.58 million. Prothena had a negative net margin of 80.68% and a negative return on equity of 16.45%.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings downgraded Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. UBS Group reissued a “buy” rating on shares of Prothena in a report on Friday, July 24th. Finally, Wall Street Zen downgraded Prothena from a “buy” rating to a “hold” rating in a research note on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Prothena Price Performance

Shares of PRTA stock opened at $8.77 on Tuesday. The company’s fifty day simple moving average is $8.64 and its two-hundred day simple moving average is $9.19. Prothena has a 1 year low of $7.73 and a 1 year high of $11.80. The stock has a market capitalization of $459.11 million, a price-to-earnings ratio of -18.27, a PEG ratio of 2.96 and a beta of -0.20.

Hedge Funds Weigh In On Prothena

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP raised its holdings in shares of Prothena by 36.0% in the 1st quarter. Rubric Capital Management LP now owns 5,000,000 shares of the biotechnology company’s stock valued at $48,600,000 after acquiring an additional 1,322,669 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Prothena by 8.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,581,443 shares of the biotechnology company’s stock worth $15,372,000 after purchasing an additional 123,679 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Prothena by 1.0% during the first quarter. Dimensional Fund Advisors LP now owns 782,603 shares of the biotechnology company’s stock worth $7,606,000 after purchasing an additional 7,396 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Prothena by 39.5% during the first quarter. Renaissance Technologies LLC now owns 607,515 shares of the biotechnology company’s stock worth $5,905,000 after purchasing an additional 172,000 shares in the last quarter. Finally, Quantinno Capital Management LP increased its position in shares of Prothena by 39.3% in the first quarter. Quantinno Capital Management LP now owns 144,299 shares of the biotechnology company’s stock worth $1,403,000 after purchasing an additional 40,681 shares during the last quarter. 97.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder William P. Scully purchased 162,000 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The shares were purchased at an average price of $8.68 per share, with a total value of $1,406,160.00. Following the completion of the acquisition, the insider owned 214,000 shares in the company, valued at $1,857,520. This trade represents a 311.54% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have acquired 1,017,500 shares of company stock valued at $8,654,850. 10.40% of the stock is owned by company insiders.

Key Headlines Impacting Prothena

Here are the key news stories impacting Prothena this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $30 target, well above the share price cited in the background. It also modestly improved its FY2026 EPS forecast, narrowing the projected loss to $0.44 from $0.47 per share. Prothena analyst coverage
• Negative Sentiment: The analyst lowered forecasts for FY2027 EPS to a loss of $1.51 from $1.28, FY2028 to earnings of $0.96 from $1.10, FY2029 to a loss of $1.48 from $1.25, and FY2030 to earnings of $2.26 from $2.37. The Q4 2026 loss forecast also widened to $0.44 per share from $0.38. These revisions temper the bullish rating and target. Prothena analyst coverage

About Prothena

Prothena Corporation plc (NASDAQ: PRTA) is a clinical-stage biotechnology company focused on discovering and developing novel medicines for serious neurodegenerative and rare peripheral diseases. Its research is centered on disease-causing proteins, including amyloid-beta, alpha-synuclein and transthyretin, with the goal of creating antibody-based therapies that address underlying disease mechanisms.

The company’s product pipeline has included birtamimab, an investigational antibody being developed for the treatment of AL amyloidosis, and prasinezumab, an investigational alpha-synuclein antibody being developed in collaboration with Roche for certain forms of Parkinson’s disease.